IndustryCompany release

MIMEDX third-quarter sales fall 45% as Medicare changes hit wound care

🇺🇸 Mimedx Group, Inc. (MDXG) · Wed 28 Oct 2026

MIMEDX reported $62M in Q3 net sales, down from $114M, while citing a court ruling on AXIOFILL and a $25M patent licence deal.

MIMEDX Group reported net sales of $62M for the third quarter of 2026, compared with $114M a year earlier, a fall of 45%. The company announced the results on 28 October 2026.

The split between its businesses was stark. Surgical sales grew 9%, whereas Wound sales dropped 71%. The company linked the wound care decline to Medicare reimbursement changes that took effect on 1 January 2026.

MIMEDX also highlighted a ruling from the US District Court for the Northern District of Georgia. The court vacated FDA's classification of AXIOFILL as a biological product that is more than minimally manipulated, and remanded both matters to the agency. The summary available does not set out what FDA will do next or how the ruling affects the product's regulatory pathway.

On the commercial side, the company announced a $25M patent licence deal with a wound care competitor. It added that it is still working with the Federal Trade Commission on Hart-Scott-Rodino (HSR) clearance for its planned acquisition of Sanara MedTech.

What it means for your team

  • Market-access teams should note how sharply a change in Medicare reimbursement can move wound care revenue, as shown by the 71% fall in MIMEDX's Wound sales.
  • Regulatory teams handling human cell and tissue products should watch the remand to FDA, since the court vacated the agency's classification of AXIOFILL as more than minimally manipulated.
  • The Sanara MedTech deal is still awaiting HSR clearance, so its timing depends on the FTC process.

Company's press release (SEC filing): Mimedx Group, Inc. ↗

Article written by VigiEye from the official source (Mimedx Group, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →